Swedish Orphan Biovitrum AB (Sobi) said on 10 May that it will pay $1.7bn to acquire CTI BioPharma Corp., buying an immediate source of revenue growth in the form of CTI’s Vonjo (pacritinib), approved in the US last year to treat myelofibrosis patients with severe thrombocytopenia. The product will also help Sobi grow its overall revenue by adding to its hematology business, already its top-selling franchise.
Sobi Set To Grow Hematology Franchise With $1.7bn CTI Biopharma Buy
Deal Prices Target Company At Big Premium
Sobi plans to capitalize on the complimentary expertise at CTI Biopharma to together boost sales of the latter firm’s myelofibrosis drug Vonjo and enhance the Swedish pharma firm’s overall growth.
More from Deals
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
More from Business
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.